Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15689MR)

This product GTTS-WQ15689MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15689MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7715MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ11985MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ8670MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ11784MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ12656MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ13976MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ1521MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ3994MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BG9924
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW